Market Research Logo

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in China was an estimated $445M. This growth is fueled by the use of immunotherapies across histologies and lines of therapy in NSCLC, as well as increased access to drugs. Currently, PD-1 inhibitors have not yet launched in China, and thus, there is significant untapped potential for this class of drugs, both in the first- and second-line settings in the Chinese market.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in China.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 China
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting
5.2.1 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
5.2.2 Tarceva (erlotinib hydrochloride)
5.2.3 Iressa (gefitinib)
5.2.4 Gilotrif (afatinib)
5.2.5 Tagrisso (osimertinib)
5.2.6 Portrazza (necitumumab)
5.2.7 Conmana (icotinib)
5.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting
5.3.1 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
5.3.2 Xalkori (crizotinib)
5.3.3 Zykadia (ceritinib)
5.3.4 Alecensa (alectinib)
5.4 Product Profiles - Major Brands, Monoclonal Antibodies
5.4.1 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
5.4.2 Opdivo (nivolumab)
5.4.3 Keytruda (pembrolizumab)
5.4.4 Tecentriq (atezolizumab)
5.5 Product Profiles - Major Brands, Other
5.5.1 Avastin (bevacizumab)
5.5.2 Cyramza (ramucirumab)
5.5.3 Vargatef/Ofev (nintedanib)
5.6 Chemotherapies
6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Therapies Targeting Novel Biomarkers
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Alternative Testing Options for Patients with Insufficient Biopsy Material
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Immune Checkpoint Inhibitors
7.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
7.2.3 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
7.2.4 Therapeutic Cancer Vaccines
7.2.5 Anti-angiogenic Therapies
7.2.6 Avastin (bevacizumab) Biosimilars
7.2.7 KRAS Inhibitors
7.2.8 Tafinlar (dabrafenib) + Mekinist (trametinib)
7.2.9 Veliparib (ABT-888)
7.2.10 Seribantumab (MM-121)
7.2.11 IMMU-132 (sacituzumab govitecan)
7.2.12 Plinabulin (NPI-2358)
7.3 Promising Drugs in Early-Stage Development
7.3.1 Immune Checkpoint Inhibitors
7.3.2 Anaplastic Lymphoma Kinase Inhibitors
7.3.3 Neurotropic Tropomyosin-Related Kinase Inhibitors
7.3.4 MET inhibitors
7.3.5 Rearranged During Transfection Inhibitors
7.3.6 Human Epidermal Growth Factor 2 Inhibitors
7.3.7 PI3K Pathway Inhibitors
8 Market Outlook
8.1 China
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed NSCLC Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research - KOLs
9.5.1 KOLs
9.6 About the Authors
9.6.1 Analyst
9.6.2 Therapy Area Director
9.6.3 Epidemiologist
9.6.4 Global Head of Healthcare
9.7 About GlobalData
9.8 Disclaimer
1.1 List of Tables
Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Prevalence of Brain and Bone Metastases in NSCLC
Table 7: Biomarker Testing Rates in Nonsquamous NSCLC
Table 8: Biomarker Testing Rates in Squamous NSCLC
Table 9: Treatment Guidelines for NSCLC
Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025
Table 11: Country Profile - China
Table 12: Leading Treatments for NSCLC, 2016
Table 13: Marketed EGFR TKIs in NSCLC
Table 14: Product Profile - Tarceva
Table 15: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 16: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 17: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 18: Safety of Tarceva
Table 19: Tarceva SWOT Analysis, 2016
Table 20: Product Profile - Iressa
Table 21: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 22: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 23: Safety of Iressa
Table 24: Iressa SWOT Analysis, 2016
Table 25: Product Profile - Gilotrif
Table 26: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 27: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 28: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 29: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 30: Safety of Gilotrif
Table 31: Gilotrif SWOT Analysis, 2016
Table 32: Product Profile - Tagrisso
Table 33: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 34: Safety of Tagrisso
Table 35: Tagrisso SWOT Analysis, 2016
Table 36: Product Profile - Portrazza
Table 37: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 38: Safety of Portrazza
Table 39: Portrazza SWOT Analysis, 2016
Table 40: Efficacy of Conmana in 2L Advanced NSCLC
Table 41: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 42: Safety of Conmana
Table 43: Conmana SWOT Analysis, 2016
Table 44: Marketed ALK TKIs in NSCLC
Table 45: Product Profile - Xalkori
Table 46: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 47: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 48: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 49: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 50: Xalkori SWOT Analysis, 2016
Table 51: Product Profile - Zykadia
Table 52: Efficacy of Zykadia
Table 53: Safety of Zykadia
Table 54: Zykadia SWOT Analysis, 2016
Table 55: Product Profile - Alecensa
Table 56: Efficacy of Alecensa
Table 57: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 58: Safety of Alecensa
Table 59: Alecensa SWOT Analysis, 2016
Table 60: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 61: Product Profile - Opdivo
Table 62: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 63: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 64: Safety of Opdivo
Table 65: Opdivo SWOT Analysis, 2016
Table 66: Product Profile - Keytruda
Table 67: Efficacy of Keytruda
Table 68: Safety of Keytruda
Table 69: Keytruda SWOT Analysis, 2016
Table 70: Product Profile - Tecentriq (atezolizumab)
Table 71: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 72: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 73: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 74: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 75: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 76: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 77: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 78: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 79: Tecentriq SWOT Analysis, 2016
Table 80: Product Profile - Avastin
Table 81: Efficacy of Avastin in Nonsquamous NSCLC
Table 82: Safety of Avastin
Table 83: Avastin SWOT Analysis, 2016
Table 84: Product Profile - Cyramza
Table 85: Efficacy of Cyramza
Table 86: Safety of Cyramza
Table 87: Cyramza SWOT Analysis, 2016
Table 88: Product Profile - Vargatef
Table 89: Efficacy of Vargatef in ADC NSCLC
Table 90: Safety of Vargatef in ADC NSCLC
Table 91: Vargatef SWOT Analysis, 2016
Table 92: Summary of Chemotherapies, 2015
Table 93: Unmet Need and Opportunity in NSCLC
Table 94: Product Profile - Yervoy (ipilimumab)
Table 95: Demographics in the Phase II NCT00527735 Trial
Table 96: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 97: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 98: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 99: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 100: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 101: Yervoy SWOT Analysis, 2016
Table 102: Product Profile - Avelumab (MSB-0010718C)
Table 103: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 104: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 105: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 106: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 107: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 108: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 109: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 110: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 111: Avelumab SWOT Analysis, 2016
Table 112: Product Profile - Durvalumab (MEDI4736)
Table 113: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 114: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 115: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 116: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 117: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 118: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 119: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 120: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 121: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 122: Durvalumab SWOT Analysis, 2016
Table 123: Product Profile - Naquotinib Mesylate (ASP8273)
Table 124: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 125: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 126: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 127: Naquotinib SWOT Analysis, 2016
Table 128: Product Profile - Olmutinib (BI 1482694; HM61713)
Table 129: Demographics in the Phase I/II NCT01588145 Trial
Table 130: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 131: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 132: Olmutinib SWOT Analysis, 2016
Table 133: Product Profile - Dacomitinib
Table 134: Demographics in the Phase II NCT00818441 Trial
Table 135: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 136: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 137: Dacomitinib SWOT Analysis, 2016
Table 138: Product Profile - Ensartinib
Table 139: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 140: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 141: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 142: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 143: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 144: Ensartinib SWOT Analysis, 2016
Table 145: Product Profile - Brigatinib
Table 146: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 147: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 148: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 149: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 150: Brigatinib SWOT Analysis, 2016
Table 151: Product Profile - CimaVax-EGF
Table 152: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 153: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 154: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 155: CimaVax-EGF SWOT Analysis, 2016
Table 156: Product Profile - Tedopi
Table 157: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 158: Efficacy of Tedopi in Advanced NSCLC
Table 159: Tedopi SWOT Analysis, 2016
Table 160: Product Profile - Anlotinib
Table 161: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 162: Anlotinib SWOT Analysis, 2016
Table 163: Product Profile - Aitan
Table 164: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 165: Aitan SWOT Analysis, 2016
Table 166: Product Profile - Fruquintinib
Table 167: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 168: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 169: Safety of Fruquintinib in Advanced Solid Tumors
Table 170: Fruquintinib SWOT Analysis, 2016
Table 171: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 172: Product Profile - Abemaciclib
Table 173: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 174: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 175: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 176: Abemaciclib SWOT Analysis, 2016
Table 177: Product Profile - Tafinlar + Mekinist
Table 178: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 179: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 180: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 181: Tafinlar + Mekinist SWOT Analysis, 2016
Table 182: Product Profile - Veliparib
Table 183: Demographics in the Phase II NCT01560104 Trial
Table 184: Efficacy of VCP in Advanced NSCLC (NCT01560104)
Table 185: Efficacy of VCP by Smoking Status (NCT01560104)
Table 186: Safety of VCP in Advanced NSCLC (NCT01560104)
Table 187: Veliparib SWOT Analysis, 2016
Table 188: Product Profile - Seribantumab (MM-121)
Table 189: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in
Table 190: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 191: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 192: MM-121 SWOT Analysis, 2016
Table 193: Product Profile - Sacituzumab govitecan (IMMU-132)
Table 194: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)
Table 195: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 196: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor
Table 197: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 198: IMMU-132 SWOT Analysis, 2016
Table 199: Product Profile - Plinabulin
Table 200: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 201: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 202: Plinabulin SWOT Analysis, 2016
Table 203: Early-Stage Clinical Development in NSCLC
Table 204: MET Status in the Phase II (NCT01610336) Trial
Table 205: Efficacy of Capmatinib + Iressa in MET+ NSCLC
Table 206: Demographics in the Phase II LURET Study
Table 207: Efficacy of Caprelsa in RET+ NSCLC
Table 208: Demographics in the Stage I of the Phase II NCT01639508 Trial
Table 209: Efficacy of Cometriq in RET+ NSCLC
Table 210: Key Events Impacting Sales for NSCLC in China, 2016
Table 211: NSCLC -Drivers and Barriers in urban China, 2015-2025
Table 212: Key Launch Dates - Part I
Table 213: Key Launch Dates - Part II
Table 214: Key Patent Expiries
Table 215 Average Body Weight and Surface Area Across the 8MM
Table 216: Average Cost of Therapy of Alimta in the 8MM
Table 217: Average Cost of Therapy of Alecensa in the 8MM
Table 218: Average Cost of Therapy of Avastin
Table 219: Average Cost of Therapy of Cyramza
Table 220: Average Cost of Therapy of Gilotrif
Table 221: Average Cost of Therapy of Iressa
Table 222: Average Cost of Therapy of Portrazza
Table 223: Average Cost of Therapy of Tagrisso
Table 224: Average Cost of Therapy of Tarceva
Table 225: Average Cost of Therapy of Vargatef
Table 226: Average Cost of Therapy of Xalkori
Table 227: Average Cost of Therapy of Zykadia
Table 228: Average Cost of Therapy of Keytruda
Table 229: Average Cost of Therapy of Opdivo
Table 230: Average Cost of Therapy of Tecentriq
Table 231: Average Cost of Therapy of Conmana
Table 232: High-Prescribing Physicians Surveyed by Country
1.2 List of Figures
Figure 1: Disease Management Flowchart for nonsquamous NSCLC
Figure 2: Disease Management Flowchart for squamous NSCLC
Figure 3: Disease Management Flowchart for EGFR+ NSCLC
Figure 4: Disease Management Flowchart for ALK+ NSCLC
Figure 5: Tarceva’s Phase III Development in NSCLC
Figure 6: Iressa’s Phase II Development in NSCLC
Figure 7: Gilotrif’s Phase III Development in NSCLC
Figure 8: Tagrisso’s Phase III Development in NSCLC
Figure 9: Portrazza’s Phase II Development in NSCLC
Figure 10: Conmana’s Phase III Development in NSCLC
Figure 11: Xalkori’s Development in NSCLC
Figure 12: Zykadia’s Development in NSCLC
Figure 13: Alecensa’s Development in NSCLC
Figure 14: Opdivo’s Development in NSCLC
Figure 15: Keytruda’s Phase III Development in NSCLC
Figure 16: Tecentriq’s Clincal Development in NSCLC
Figure 17: Avastin’s Phase III Development in NSCLC
Figure 18: Cyramza’s Phase III Development in NSCLC
Figure 19: Vargatef’s Phase II Development in NSCLC
Figure 20: NSCLC - Phase II/III Pipeline, 2016, Part I
Figure 21: NSCLC - Phase II/III Pipeline, 2016, Part II
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025
Figure 23: Yervoy’s Clinical Development in NSCLC
Figure 24: Clinical and Commercial Positioning of Yervoy
Figure 25: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025
Figure 26: Avelumab’s Development in NSCLC
Figure 27: Clinical and Commercial Positioning of Avelumab
Figure 28: Durvalumab’s Clinical Development in NSCLC
Figure 29: Clinical and Commercial Positioning of Durvalumab
Figure 30: Naquotinib’s Clincal Development in NSCLC
Figure 31: Clinical and Commercial Positioning of Naquotinib
Figure 32: Olmutinib’s Clincal Development in NSCLC
Figure 33: Clinical and Commercial Positioning of Olmutinib
Figure 34: Dacomitinib’s Clinical Development in NSCLC
Figure 35: Clinical and Commercial Positioning of Dacomitinib
Figure 36: Ensartinib’s Clinical Development in NSCLC
Figure 37: Clinical and Commercial Positioning of Ensartinib
Figure 38: Brigatinib’s Clinical Development in NSCLC
Figure 39: Clinical and Commercial Positioning of Brigatinib
Figure 40: CimaVax-EGF’s Clinical Development in NSCLC
Figure 41: Clinical and Commercial Positioning of CimaVax-EGF
Figure 42: Tedopi’s Clinical Development in NSCLC
Figure 43: Clinical and Commercial Positioning of Tedopi
Figure 44: Anlotinib’s Clinical Development in NSCLC
Figure 45: Clinical and Commercial Positioning of Anlotinib
Figure 46: Aitan’s Clinical Development in NSCLC
Figure 47: Clinical and Commercial Positioning of Aitan
Figure 48: Fruquintinib’s Clinical Development in NSCLC
Figure 49: Clinical and Commercial Positioning of Fruquintinib
Figure 50: Clinical Development of Avastin Biosimilars in NSCLC
Figure 51: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025
Figure 52: Abemaciclib’s Clinical Development in NSCLC
Figure 53: Clinical and Commercial Positioning of Abemaciclib
Figure 54: Tafinlar + Mekinist’s Clinical Development in NSCLC
Figure 55: Clinical and Commercial Positioning of Tafinlar + Mekinist
Figure 56: Veliparib’s Clinical Development in NSCLC
Figure 57: Clinical and Commercial Positioning of Veliparib
Figure 58: MM-121’s Clinical Development in NSCLC
Figure 59: Clinical and Commercial Positioning of MM-121
Figure 60: IMMU-132’s Clinical Development in NSCLC
Figure 61: Clinical and Commercial Positioning of IMMU-132
Figure 62: Plinabulin’s Clinical Development in NSCLC
Figure 63: Clinical and Commercial Positioning of Plinabulin
Figure 64: Sales for NSCLC in urban China by Drug Class, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report